/
/
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
A subscription to JoVE is required to view this content. Sign in or start your free trial.
1Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Hospital University Federation OncoAge,Université Côte d’Azur, 2Institute for Research on Cancer and Aging in Nice (Inserm U1081 and CNRS 7284),Université Côte d’Azur, 3Hospital-Integrated Biobank (BB-0033-00025), Pasteur Hospital,Université Côte d’Azur
Chapters
- 00:04Title
- 01:13Preparation of Tumor Tissue Samples
- 01:53Preparation of Cytology Samples
- 02:56PD-L1 Staining Assay
- 04:27Interpretation of the PD-L1 Staining
- 05:08Results: Analysis of the PD-L1 Staining
- 06:23Conclusion
To expand the ability of laboratories worldwide to assess the eligibility of patients with lung cancer for treatment with pembrolizumab, in a reliable and reproducible manner, we developed an assay that uses the 22C3 antibody concentrate on a widely available immunohistochemical autostainer, for both biopsy and cytology specimens.
